ArticleScientific reports2025
Salivary kynurenine pathway metabolites as potential non-invasive markers of glandular dysfunction in Sjögren's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- On the correlation of tryptophan and its kynurenine pathway metabolites level in blood, saliva and urine in systemic sclerosis patients.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's disease (SjD) is an autoimmune disorder characterized by salivary gland dysfunction and systemic manifestations. This study aimed to evaluate kynurenine (Kyn) pathway metabolites in saliva and investigate their clinical relevance in SjD. Saliva samples were collected from 39 SjD patients and 32 healthy controls (HCs). Concentrations of tryptophan, Kyn, quinolinic acid (QA), and kynurenic acid (KA), as well as inferred enzyme activities, were measured using ELISA. Receiver operating characteristic curve analyses were conducted, and correlations with disease activity indices and unstimulated whole salivary flow rates (UWSFR), were assessed. SjD patients exhibited significantly higher salivary KA levels (p < 0.001) and lower QA levels (p < 0.0001) compared with HCs. Ratios of QA to Kyn and KA to Kyn were also significantly altered in the SjD group. Salivary QA demonstrated excellent discriminatory ability (area under the curve > 0.85, sensitivity 0.87, specificity 0.76, p < 0.001) for distinguishing SjD from HCs. Among various clinical parameters, salivary QA levels showed a strong inverse correlation with UWSFR (r = - 0.596, p < 0.001). Salivary Kyn pathway metabolites, particularly QA, may serve as non-invasive biomarkers reflecting salivary gland dysfunction in SjD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.